Clinical Trial

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2025 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-08-02; most recent amendment 2025-02-27.
Trial Details
NCT Number NCT05487170
Lead Sponsor Ranok Therapeutics (Hangzhou) Co., Ltd.
Conditions Advanced Solid Tumor, DLBCL
Enrollment 32 participants
Start Date 2022-07-12
Primary Completion 2025-06-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-04